Type 2 Diabetes Medication Refills Treatment
Covered by Aetna in California

Metformin 500–2000mg daily in divided doses (Tier 1, first-line per ADA 2026 Standards of Care); empagliflozin 10–25mg daily or dapagliflozin 10mg daily (SGLT-2 inhibitors — preferred in patients with established ASCVD, heart failure, or CKD per ADA 2026 comorbidity-driven algorithm); dulaglutide 0.75–1.5mg weekly SQ or semaglutide 0.5–2mg weekly SQ (GLP-1 RA — preferred with ASCVD, obesity, or need for weight loss)

Glipizide 5–20mg daily or glimepiride 1–4mg daily (sulfonylureas — Tier 1 generics, de-emphasized in ADA 2026 but appropriate when cost limits preferred agents); sitagliptin 100mg daily (DPP-4 — low hypoglycemia risk, renal dose-adjust); tirzepatide 5–15mg weekly (dual GIP/GLP-1, most potent A1c and weight reduction per ADA 2026 Rec 8.20 — requires PA + step therapy); basal insulin glargine 10–40 units at bedtime for patients with A1c >10% or symptomatic hyperglycemia

Yes — metformin is Tier 1 covered on all Aetna CA commercial plans (~$4–$10/month). SGLT-2 inhibitors are Tier 2–3 and typically covered with formulary copay ($40–$80/month on most plans) after PA on some plans. GLP-1 agonists require PA and documented step therapy through metformin; if approved, typically Tier 3 specialty copay ($60–$120/month on most commercial plans). GLP-1 refills for stable, previously approved patients are appropriate for telehealth management.

ADA Standards of Care 2026 shifts to a comorbidity-driven model: drug selection is guided by ASCVD, heart failure, CKD, and obesity — not glycemic targets alone. SGLT-2 inhibitors are organ-protection drugs (reduce HF hospitalization, CKD progression) and may be initiated independent of metformin. GLP-1 RAs provide CV risk reduction (MACE benefit) and clinically significant weight loss. Continuous glucose monitoring (CGM) is now standard of care per ADA 2026. Insulin refills require stable established dosing; new insulin starts or dose titration in poorly controlled diabetes may need in-person endocrinology referral. Telehealth refills are appropriate for type 2 diabetes only; type 1 diabetes management is outside TDMD scope.

Yes, for most Aetna CA commercial plans, GLP-1 receptor agonists for type 2 diabetes require prior authorization that includes documented prior use of metformin (step therapy). If you have a clinical reason metformin is not appropriate — such as eGFR below 30, intolerance due to GI side effects, or a comorbidity profile where ADA 2026 guidelines recommend GLP-1 as first-line (established ASCVD, obesity, high CV risk) — Dr. Bhavsar can document medical necessity for bypass of the step therapy requirement. The PA process typically takes 3–7 business days. Refills for patients already approved and stable on a GLP-1 do not require new PA.

Yes, with appropriate clinical context. Insulin refills are appropriate for patients on stable, established dosing regimens — for example, basal insulin glargine at a fixed nightly dose that has been working well. Dr. Bhavsar will review your glucose log or CGM data and confirm the current dose is appropriate. New insulin starts, significant dose titration, or management of recurrent hypoglycemia are more complex and may require in-person endocrinology evaluation. All basal insulin formulations (glargine biosimilars, detemir) are covered on Aetna CA pharmacy benefit, typically at Tier 2.

SGLT-2 inhibitors require PA on some Aetna CA plan tiers. If your claim was denied, Dr. Bhavsar can document medical necessity based on your comorbidity profile. ADA 2026 explicitly recommends SGLT-2 inhibitors as foundational therapy for patients with heart failure or CKD — independent of glucose control — which provides strong support for PA approval. Your visit summary will include the clinical rationale (ASCVD, CHF, CKD stage, BMI, A1c) needed for a PA request or denial appeal.

CGMs (FreeStyle Libre, Dexcom G7) are covered under the Aetna CA pharmacy benefit for members with type 2 diabetes on insulin, and on some plans for patients on non-insulin diabetes medications. ADA 2026 designates CGM as standard of care. Dr. Bhavsar can write a CGM prescription during your diabetes refill visit, and the visit documentation supports PA criteria. Coverage tiers and copays vary by plan — FreeStyle Libre sensors are typically Tier 2–3 ($30–$80/month after plan deductible).

Yes. Aetna commercial plans cover telehealth visits for Type 2 Diabetes Medication Refills in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your diabetes medication refills visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your diabetes medication refills symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.